East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Levomilnacipran Extended-Release Capsules, 20 mg, 40 mg, 80 mg, and 120 mg. Aurobindo Pharma’s Levomilnacipran Extended-Release Capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), FETZIMA® (levomilnacipran) extended-release capsules manufactured by Allergan Sales, LLC.

Levomilnacipran Extended-Release Capsules are indicated for:

• The treatment of Major Depressive Disorder (MDD).